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Abstract 
Background: Oral potentially malignant disorders harbour variable and 
unpredictable risk for squamous carcinoma development. Whilst current 
management strategies utilise histopathological diagnoses, dysplasia grading and 
targeted intervention for ‘high risk’ lesions, clinicians are unable to predict malignant 
potential. 
Methods: Detailed, retrospective clinico-pathological analysis of potentially 
malignant lesions undergoing malignant transformation, from a 590 patient cohort 
treated by interventional laser surgery and followed for a mean of 7.3 years, was 
undertaken. Clinical outcome was documented at study census date (31 December 
2014).  
Results: 99 patients (16.8%) developed cancer: 71 (12%) seen ‘unexpectedly’ upon 
excision and 28 (4.8%) progressing to malignancy at a median of 87.3 months post-
surgery. 30 ‘unexpected’ excisions were micro-invasive (42.3%) arising primarily in 
severely dysplastic precursors (75%) at ventro-lateral tongue and floor of mouth sites 
(54.5%); 1 patient (1.4%) had a cancer-related death, whilst 58 (81.7%) were 
disease free. 19 of 28 ‘progressive’ cancers (67.9%) arose at new sites, with 
erythroleukoplakia a significant predictor of malignancy (p=0.0019). 9 (32.1%) 
developed at the same precursor site, with 6 (77.7%) on the ventro-lateral tongue 
and floor of mouth. 3 (10.7%) were micro-invasive, 9 patients (32.1%) died from 
metastatic disease and 12 (42.9%) were disease free (p<0.001). 
Conclusion: Squamous carcinoma may arise at the site of a precursor lesion as 
transformation or new-site development via field cancerisation. Whilst interventional 
surgery facilitates early diagnosis and treatment of occult disease, thus reducing risk 
from same-site transformation, new-site cancer is a significant long-term risk for 
potentially malignant disorder patients. 
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Introduction 
Invasive oral squamous cell carcinomas (OSCC) are preceded by potentially 
malignant disorders (PMD), distinct mucosal lesions including leukoplakia, 
erythroplakia, or erythroleukoplakia and widespread disorders such as proliferative 
verrucous leukoplakia (PVL)1,2. Characteristic of PMD is the variable presence of 
epithelial disorganisation and dysmaturation, identified microscopically as dysplasia 
and subjectively graded for severity1,2. The natural history of PMD remains poorly 
understood, however, with varying malignant transformation rates quoted between 
0.13 to 36.4% occurring over periods of 1 to 30 years3; systematic review estimates 
an overall 12% cancer risk over a mean transformation time of 4.3 years4.  
In a recent editorial, Guneri & Epstein3 highlighted clinicians’ inability to predict PMD 
behaviour or quantify the risk of malignant transformation emphasizing our poor 
understanding of carcinogenesis. Contemporary PMD management relies upon 
incision biopsy for histological confirmation followed by surgical excision for definitive 
diagnosis and effective treatment of lesions deemed ‘high risk’5-7. Whilst controversy 
may exist over the assignment of risk, early diagnosis and intervention during the 
progression of dysplasia to OSCC should have potential to improve patient 
prognosis and reduce morbidity and mortality; this hypothesis remains largely 
unproven however1. 
Long-term observational studies of PMD patients have been advised to improve 
knowledge of disease progression, to determine predictors of clinical outcome and 
establish realistic time-scales for malignant transformation3,8. 
In a previous study we demonstrated a degree of efficacy for interventional 
management by reviewing clinical outcome in 590 ‘high risk’ PMD patients 
undergoing CO2 laser surgery and followed for up to 19 years post-treatment (mean 
7.3yrs); 438 patients (74.2%) became disease free, 53 (9%) had persistent disease, 
and 99 (16.8%) developed OSCC.7 Features associated with malignant 
transformation included eryrthroleukoplakic appearance, presence of severe 
dysplasia in initial biopsies and origin on ventro-lateral tongue and floor of mouth 
sites7. 
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The specific purpose of this paper is to re-evaluate the clinico-pathological data for 
these 99 transforming PMD patients and thereby identify features predictive of 
cancer, enhance understanding of the carcinogenic pathway and clarify the likely 
time-course for malignant transformation in PMD patients. 
  
Method 
Caldicott Approval from Newcastle University / Newcastle upon Tyne Hospitals NHS 
Foundation Trust facilitated anonymized, retrospective data collection from medical 
records, operating books and original pathology reports from PMD patients treated 
by laser in Maxillofacial Surgery between August 1996 and December 2014. 
Inclusion criteria for this analysis required patients to have been new presentations 
of single-site PMD disease with a confirmed diagnosis of OSCC. Demographic and 
clinico-pathological data required patient age and sex, appearance and site of 
presenting PMD, histopathology diagnoses (pre-operative incision and post-laser 
excision biopsies), OSCC appearance, site and histopathology, and clinical outcome 
at study census date (31 December 2014).  
All biopsies and CO2 laser surgeries were carried out by the first author (PJT), or 
colleagues working under direct supervision, to well-established guidelines and 
within 6 to 12 weeks of PMD presentation to avoid disease progression5. Formalin-
fixed tissue specimens were assessed via standardized histopathology examination 
by oral pathologists at the Royal Victoria Infirmary using agreed diagnostic criteria, 
peer review and consensus grading7. The World Health Organization (WHO) system 
was used and dysplasia classified as mild, moderate and severe or carcinoma-in-situ 
(CiS); micro-invasive and invasive OSCC categories were distinguished. Diagnoses 
of hyperkeratosis, lichenoid inflammation (LI), PVL and chronic hyperplastic 
candidosis (CHC) were also made.  
All OSCC patients were referred to Newcastle multi-disciplinary head and neck 
clinics for further assessment and management along established oncology care 
pathways.   Clinical outcomes were stratified as: disease free, further disease or 
cancer-related death.  
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Statistical Analyses 
Descriptive Statistics were used to summarise patient demography, clinico-
pathological features, clinical outcome and follow-up data. Fisher’s exact test, 
Student’s t-test and Chi-square testing were used as appropriate to compare clinico-
pathological features, assessed as categorical variables, potentially influencing 
clinical outcome. Due to low study numbers in each category, P values were 
computed using Monte Carlo simulation and natural logarithmic transformation 
applied prior to analyses of time influence.  Univariate Cox regression analyses of 
clinico-pathological factors potentially influencing time to malignant transformation, 
including patient sex, age, precursor lesion site, appearance and histopathology 
were also performed. Statistical analyses were carried out using SPSS, version 19.0 
(Statistical Package for the Social Sciences, Chicago, IL, USA), R Environment for 
Statistical Computing (version 3.2.5) and SAS/STAT® 9.3 software (SAS Institute Inc, 
Cary, USA). 
 
Results 
Two distinct OSCC presentations were recognised in the 99 patients: 71 were 
identified immediately and ‘unexpectedly’ upon histopathological assessment of laser 
excision specimens, whilst 28 cases ‘progressed’ to malignancy at same or new 
sites during follow-up.  
 
Unexpected OSCC Diagnosis 
Data for the 71 ‘unexpected’ OSCC cases are listed in Table 1, comprising 50 males 
(age range 47-83yrs; mean 62.6yrs) and 21 females (age range 33-89yrs; mean 
65.3yrs). Initial lesion appearance included 38 leukoplakias (53.5%), 29 
erythroleukoplakias (40.9%) and 4 erythroplakias (5.6%). 48 lesions (54.5%) arose 
on the ventro-lateral tongue and floor of mouth, with other individual sites less 
frequently involved. 66 presenting lesions (93%) exhibited dysplastic features on 
histopathological examination, with severe dysplasia or CiS in 52 (73%). All OSCCs 
were completely excised by laser, with 30 (42.3%) classed as micro-invasive. 
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Clinical outcome at study census showed 58 patients disease free (81.7%), 12 
developing further PMD disease (16.9%) and 1 OSCC-related death (1.4%). 
Progression to OSCC 
Table 2 documents clinico-pathological profiling for precursor PMDs and subsequent 
OSCC lesions in the 28 ‘progression’ cases including cancer site, time to malignant 
transformation and clinical outcome. Patients comprised 16 males (age range 34-
84yrs; mean 60.7yrs) and 12 females (age range 45-92yrs; mean 65.3yrs). 19 
precursor lesions presented as leukoplakia (68%), with 6 erythroleukoplakias (21%) 
and 3 erythroplakias (11%). 15 (53.6%) arose on the ventro-lateral tongue and floor 
of mouth, with other sites again infrequently affected. 27 lesions (96.4%) exhibited 
dysplasia on initial biopsy, with 17 (60.7%) showing severe dysplasia or CiS. 18 
OSCCs presented as erythroleukoplakia (64%) with 10 leukoplakias (36%); only 3 
OSCCs (10.7%) were micro-invasive. In terms of clinical outcome, 12 patients 
(42.9%) were disease free, 7 (25%) developed further PMD and 9 (32.1%) died from 
metastatic OSCC.  
Change in lesion appearance to erythroleukoplakia was a specific OSCC predictor 
within the ‘progression’ group (Fisher’s exact test: p=0.0019), whilst comparison 
between ‘unexpected’ and ‘progression’ groups highlighted both an increased 
proportion of invasive OSCCs (Chi-squared test: x2=8.99; p=0.004) and poor clinical 
outcome including OSCC-related deaths (Chi-squared test: x2=23.75; p<0.001) as a 
result of ‘progressive’ disease. Patient sex, age, precursor lesion site, appearance 
and histopathology were not predictive of behaviour; Table 3.  
9 OSCCs arose at the same-site as PMD precursor, with 6 (77.7%) arising on 
ventro-lateral tongue and floor of mouth. For 19 OSCCs developing at new-sites, 
there were no clear relationships between precursor and subsequent site, although 
ventro-lateral tongue and floor of mouth precursors were less frequent (8 or 42.2%). 
Same-site transformation occurred between 3 and 48 months (mean 28 months), 
whilst new-site OSCC generally took longer, from 9 to 204 months (mean 61.3 
months), although the difference was not statistically significant (Student’s t-test: 
p=0.21). Median time to malignancy in the 28 cases was 87.3 months (95% CI 59.9 
to 149.2). Analyses of clinico-pathological variables potentially influencing time to 
malignancy in the 28 cases are summarised in Table 4, but none were significant.  
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Discussion 
Transformation of an identifiable precursor lesion into invasive OSCC must rank as 
the ultimate PMD treatment failure, yet prediction of ‘high-risk’ behaviour and cancer 
development remains elusive in clinical practice. Published transformation rates vary 
widely between 0.13 and 50%, with ‘average’ times ranging from 0.5 to 17 years3,9-16; 
such data are unhelpful in counselling individual patients in clinical practice, although 
it is generally believed that risk increases for lesions exhibiting severe dysplasia and 
over prolonged follow-up11,13,14. Warnakulasuriya & Ariyawardana17 reviewed 24 
observational studies of oral leukoplakia and identified advanced age, females, 
lesion greater than 200mm2 in size, non-homogenous clinical appearance and 
severe dysplasia as high risk. Other authors, however, have not found clinical or 
pathological observations to correlate reliably with malignant transformation, with 
currently available biomarkers of little practical use3,18-20.  
This paper presented a clinico-pathological review of 99 PMD patients developing 
OSCC in a 590 cohort undergoing laser treatment7. Identifying and excising 71 
‘unexpected’ cancers, particularly early stage micro-invasive tumours, is undoubtedly 
a diagnostic and treatment success, demonstrating efficacy of intervention and 
supporting the hypothesis that patient morbidity and mortality can be reduced1,7,21; 
81.7% of these patients were disease free with only 1 cancer-related death. In 
contrast, a further 28 patients developed post-treatment OSCC, 19 at new sites, at a 
median time of 87.3 months. Whilst long-term follow-up facilitated early OSCC 
recognition, it is notable that these clinical outcomes were significantly worse with 9 
cancer-related deaths and only 42.9% of patients disease free at census (p<0.001).   
Few studies have reported upon defined PMD cohorts undergoing standardised 
treatment, so it is difficult to compare data with other publications. Saito et al22 
reported 6.3% transformation in 142 patients treated by surgery for leukoplakia, 
although only 91 lesions were dysplastic, whilst Ho et al15 observed a 25% rate in 91 
patients monitored over a median 40.3 month period, but provided no treatment 
details. We have previously identified occult OSCC in 9% of 169 laser excisions23, 
but this current series presents the largest and longest observed cohort. 
The clinician’s dilemma remains how to identify and predict PMDs at greatest risk of 
cancer. Precursor lesions in this Northern England population most frequently 
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presented as leukoplakia (57) on ventro-lateral tongue and floor of mouth sites (63), 
consistent with previous reports and reflective of inherent disease susceptibility5,6,24.  
Of clinical relevance is the observation that ventro-lateral tongue and floor of mouth 
were at particular risk of same-site malignant transformation, both ‘unexpected’ and 
‘progressive’, although seemed less likely to be the primary focus in cases of new-
site OSCC. Erythroleukoplakia, either as a precursor in ‘unexpected’ cases or as a 
change in appearance during ‘progression’ was associated with OSCC development, 
confirming earlier observations and highlighting the importance of its early 
recognition7,17. 
Review of precursor histopathology did not show a reliable predictive role, although 
52 of 71 ‘unexpected’ (73.2%) and 17 of 28 ‘progression’ cases exhibited severe 
dysplasia or CiS on initial biopsy, supporting earlier reports regarding high-grade 
dysplasia risk13,17. Finding micro-invasive cancers in substantive numbers within the 
‘unexpected’ group emphasised not only the difficulty in identifying early cancer 
change clinically21, but also the efficacy of intervention via excision because clinical 
outcome was demonstrably better in these patients7. In contrast, despite early 
recognition during follow-up, the increased number of invasive OSCCs in the 
‘progression’ group was associated with poor clinical outcome and an increased 
number of cancer-related deaths. 
Time to malignancy varied substantially between 3 to 204 months, although same-
site transformation generally occurred earlier than new-site cancer development, 
probably reflecting variable influence of field change cancerization. Lack of statistical 
significance in the ‘progression’ group may relate to the limited sample size of 28 
cases. 
It is the authors’ opinion that clarifying terminology will assist future observational 
studies and therefore advise restricting the term ‘malignant transformation’ to PMDs 
exhibiting same-site OSCC, whilst distinguishing ‘cancer development’ for those with 
new-site disease. Intervention to excise localised lesions may indeed prevent or 
effectively treat ‘malignant transformation’ but the risk of subsequent ‘cancer 
development’ remains. Active surveillance during patient follow-up is thus an 
essential component of interventional therapy and allows early signs of further 
disease to be recognised and treatment initiated5-7. 
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The precise interplay of epidemiological, diagnostic, histopathological, and bio-
molecular factors remains complex, however, with carcinogenesis arising from 
intrinsic and extrinsic influences acting both synchronously and metachronously 
throughout ill-defined areas of mucosal field change1.  
Although this was neither a prospective nor randomized controlled trial and was 
limited in population size from a single-centre, review of clinico-pathological and 
patient outcome data has provided additional insight into cancer risk within a defined 
PMD cohort. Interventional laser surgery facilitates early diagnosis and effective 
treatment of occult ‘unexpected’ OSCC and reduces morbidity and mortality from 
same-site transformation, but new-site cancer retains lethality and is a significant 
long-term risk for all PMD patients. 
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TABLE 1: CLINICO-PATHOLOGICAL FEATURES OF PRECURSOR PMD LESIONS IN WHICH 
LASER EXCISION REVEALED UNEXPECTED SCC (Number = 71) 
Year Age Sex PMD 
Lesion 
Site Incision Biopsy 
Histopathology 
SCC 
Histopathology 
Clinical 
Outcome 
1997 89 F ELK Buccal Severe Dysplasia miSCC Further PMD 
1997 64 M LK Lateral Tongue Moderate Dysplasia SCC Disease Free 
1997 71 F LK Buccal Hyperkeratosis SCC Disease Free 
1998 50 M ELK Lateral Tongue CiS miSCC Disease Free 
1998 62 M ELK Lateral Tongue Severe Dysplasia SCC Disease Free 
1998 69 F LK FOM CiS miSCC Further 
1998 64 M ELK Fauces / RM Severe Dysplasia SCC Further 
1998 51 F ELK Lateral Tongue Severe Dysplasia miSCC Disease Free 
1998 54 M EK Fauces / RM CiS SCC Disease Free 
1998 72 M LK Lateral Tongue CiS SCC Disease Free 
1998 83 F ELK Lateral Tongue Severe Dysplasia SCC Disease Free 
1998 52 M ELK Buccal CHC SCC Disease Free 
1999 48 M LK Lateral Tongue Severe Dysplasia SCC Disease Free 
1999 66 F LK Lateral Tongue Severe Dysplasia SCC Disease Free 
1999 69 M LK FOM Moderate Dysplasia miSCC Disease Free 
1999 58 F ELK Lateral Tongue Severe Dysplasia SCC Disease Free 
1999 81 M ELK FOM Moderate Dysplasia SCC Disease Free 
1999 56 M ELK FOM CiS miSCC Disease Free 
1999 49 M ELK Palate CiS miSCC Disease Free 
1999 61 M ELK FOM CiS miSCC Disease Free 
1999 47 M ELK Lateral Tongue Severe Dysplasia SCC Disease Free 
1999 68 M LK Buccal Severe Dysplasia SCC Further PMD 
2000 68 M LK Ventral Tongue CiS miSCC Further PMD 
2000 66 F LK Palate CiS SCC Disease Free 
2000 67 M LK Lateral Tongue CiS SCC Disease Free 
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2000 68 M LK FOM CiS miSCC Disease Free 
2000 59 M LK Palate CiS miSCC Disease Free 
2001 59 M EK Fauces / RM CiS miSCC Disease Free 
2001 67 M ELK Fauces CiS miSCC Disease Free 
2001 69 F LK Buccal CiS miSCC Disease Free 
2002 69 M LK Ventral Tongue Hyperkeratosis SCC Disease Free 
2002 83 M ELK FOM Severe Dysplasia SCC Disease Free 
2003 84 F LK Alveolus Severe Dysplasia miSCC Disease Free 
2003 61 F LK Lateral Tongue Severe Dysplasia miSCC Disease Free 
2003 73 M LK Ventral Tongue CiS miSCC Disease Free 
2003 57 F LK Lateral Tongue CiS SCC Further PMD 
2004 68 F LK Lateral Tongue Hyperkeratosis + 
Lichenoid 
Inflammation 
miSCC Disease Free 
2004 73 M LK FOM CiS miSCC Disease Free 
2004 55 M ELK Lateral Tongue CiS miSCC Disease Free 
2004 79 M LK FOM Severe Dysplasia miSCC Disease Free 
2004 81 M ELK Lateral Tongue CiS SCC Disease Free 
2004 61 M LK Lateral Tongue CiS SCC Further PMD 
2004 77 F LK Ventral Tongue Mild Dysplasia SCC Disease Free 
2004 65 F LK FOM Severe Dysplasia SCC Disease Free 
2005 59 M ELK FOM Severe Dysplasia SCC SCC Death 
2005 49 M ELK FOM CiS SCC Disease Free 
2005 48 M ELK Lateral Tongue Severe Dysplasia miSCC Disease Free 
2006 60 M LK Dorsum Tongue Mild Dysplasia miSCC Further PMD 
2006 51 M ELK RM Severe Dysplasia SCC Disease Free 
2007 60 M LK Lateral Tongue CiS SCC Disease Free 
2007 64 F ELK Lateral Tongue Moderate Dysplasia SCC Disease Free 
2007 82 M EK Fauces CiS SCC Disease Free 
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2007 52 M LK Lateral Tongue Moderate Dysplasia SCC Disease Free 
2007 59 M ELK Buccal Moderate Dysplasia miSCC Disease Free 
2007 33 F LK Dorsum Tongue PVL SCC Disease Free 
2007 63 M ELK Ventral Tongue Severe Dysplasia SCC Disease Free 
2007 62 M EK Palate Severe Dysplasia miSCC Disease Free 
2007 74 F LK Buccal Mild Dysplasia miSCC Disease Free 
2008 70 M LK Lateral Tongue Mild Dysplasia  + 
Lichenoid 
Inflammation 
SCC Further PMD 
2008 61 M LK FOM Severe Dysplasia SCC Disease Free 
2009 67 M LK Ventral Tongue Moderate Dysplasia SCC Disease Free 
2010 65 M ELK FOM Severe Dysplasia SCC Disease Free 
2010 58 M LK Lateral Tongue Mild Dysplasia miSCC Disease Free 
2011 66 M LK FOM Severe Dysplasia miSCC Disease Free 
2012 74 F ELK Alveolus Mild Dysplasia SCC Disease Free 
2012 65 M LK Fauces Severe Dysplasia SCC Further PMD 
2013 67 M ELK Lateral Tongue CiS SCC Further PMD 
2013 57 F LK FOM Severe Dysplasia SCC Disease Free 
2013 51 M ELK Lateral Tongue Severe Dysplasia miSCC Disease Free 
2013 58 M LK Lateral Tongue Mild Dysplasia miSCC Further PMD 
2013 36 F ELK Fauces CiS SCC Disease Free 
 
LK: leukoplakia; ELK: erythroleukoplakia; EK: erythroplakia; FOM: floor of mouth; RM: retromolar 
region; PVL: proliferative verrucous leukoplakia; CiS: carcinoma-in-situ; miSCC: micro-invasive 
squamous cell carcinoma; SCC: squamous cell carcinoma; PMD: potentially malignant disorder 
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TABLE 2: CLINICO-PATHOLOGICAL PROFILING OF PRECURSOR PMD LESIONS AND THEIR 
TRANSFORMED SCCs (Number = 28) 
 
Year Age Sex PMD 
Lesion 
Precursor 
Histopathology 
Precursor 
Site 
SCC 
Lesion 
SCC 
Site 
SCC 
Histopathology 
MT  
(months) 
MT  
Site 
Clinical 
Outcome 
1996 88 F LK Moderate Dysplasia Buccal LK Alveolus SCC 204 New  SCC Death 
1996 45 F LK Hyperkeratosis  + 
Lichenoid 
Inflammation 
Alveolus LK Palate SCC 30 New SCC Death 
1997 58 M LK CiS Fauces / RM ELK RM miSCC 48 Same SCC Death 
1998 72 M EK CiS Fauces / RM LK Lateral Tongue SCC 8 New Disease Free 
1998 76 M EK CiS Buccal ELK Alveolus SCC 86 New SCC Death 
1999 61 F LK Moderate Dysplasia Ventral 
Tongue 
LK Lateral Tongue miSCC 15 New SCC Death 
1999 92 F LK Moderate  Dysplasia Lateral 
Tongue 
LK Buccal SCC 12 New Disease Free 
2000 51 F LK Moderate  Dysplasia Palate ELK Alveolus SCC 124 New Further PMD 
2000 84 M LK CiS Lateral 
Tongue 
ELK FOM SCC 133 New Disease Free 
2000 62 M LK CiS Labial 
Commissure 
ELK Dorsum 
Tongue 
SCC 147 New SCC Death 
2001 56 F ELK CiS Fauces / RM ELK Palate SCC 158 New Disease Free 
2002 60 M LK Moderate  Dysplasia Labial 
Commissure 
LK Labial SCC 9 New Disease Free 
2003 47 M LK Severe Dysplasia Lateral 
Tongue 
ELK Lateral Tongue miSCC 35 Same Disease Free 
2003 72 M LK CiS Lateral 
Tongue 
LK FOM SCC 12 New Further PMD 
2003 54 F LK Moderate  Dysplasia Alveolus ELK Buccal SCC 69 New Further PMD 
2003 48 M ELK Severe Dysplasia Lateral 
Tongue 
ELK Lateral Tongue SCC 59 Same Further PMD 
2006 62 F LK Mild Dysplasia Lateral 
Tongue 
ELK Palate SCC 18 New SCC Death 
2007 59 M ELK Severe Dysplasia Lateral 
Tongue 
ELK Palate SCC 70 New Disease Free 
2007 58 M LK CiS Fauces / RM ELK FOM SCC 17 New SCC Death 
2008 74 F LK Mild Dysplasia Palate ELK Palate SCC 3 Same Disease Free 
2008 58 M LK Severe Dysplasia FOM ELK FOM SCC 4 Same Disease Free 
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2008 74 F LK Mild Dysplasia Buccal LK Labial SCC 28 New SCC Death 
2008 73 M EK CiS FOM LK FOM SCC 16 Same Disease Free 
2009 62 F ELK Severe Dysplasia Lateral 
Tongue 
ELK Lateral Tongue SCC 24 Same Disease Free 
2010 34 M LK Mild Dysplasia Ventral 
Tongue 
ELK Ventral Tongue SCC 42 Same Further PMD 
2010 51 M ELK Severe Dysplasia Lateral 
Tongue 
ELK Fauces SCC 9 New Further PMD 
2010 59 M ELK  Severe Dysplasia FOM ELK Labial SCC 16 New Disease Free 
2012 65 F LK Severe Dysplasia FOM LK FOM SCC 21 Same Further PMD 
 
 
LK: leukoplakia; ELK: erythroleukoplakia; EK: erythroplakia; FOM: floor of mouth; RM: retromolar 
region; PVL: proliferative verrucous leukoplakia; CiS: carcinoma-in-situ; miSCC: micro-invasive 
squamous cell carcinoma; SCC: squamous cell carcinoma; PMD: potentially malignant disorder 
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TABLE 3: COMPARISON OF CLINICO-PATHOLOGICAL VARIABLES BETWEEN ‘UNEXPECTED’ 
OSCC (n=71) AND PROGRESSION OSCC (n=28)  
Clinico-Pathological Variable      Chi Square            p-Value 
Sex          1.59             0.25 
Age           0.79             0.50 
Precursor Site         12.56             0.24 
PMD Lesion Appearance           3.59             0.16 
Precursor Histopathology             5.65             0.74 
miSCC vs SCC           8.99             0.004 
Clinical Outcome         23.75           <0.001 
 
            miSCC: micro-invasive squamous cell carcinoma; SCC: oral squamous cell carcinoma 
 
 
TABLE 4: CLINICO-PATHOLOGICAL VARIABLES INFLUENCING TIME TO CANCER 
DEVELOPMENT (PROGRESSION GROUP n=28)   
Clinico-Pathological Variable            p-Value 
Sex             0.58 
Age             0.46 
Precursor Site*                - 
PMD Lesion Appearance             0.55 
Precursor Histopathology               0.96 
 
*Insufficient data available in category for analysis 
 
 
 
